Purpose Pharmacokinetic considerations in patients who have undergone Roux-en-Y gastric bypass (RYGB) are explored. Summary The prevalence of obesity, especially morbid obesity, has dramatically ...

Pharmacokinetic Considerations in Roux-en-Y Gastric Bypass Patients April Smith; Brian Henriksen; Andrew Cohen Disclosures Am J Health Syst Pharm. 2011;68 (23):2241-2247.

In our comparison of uncut Roux-en-Y with Roux-en-Y reconstruction, uncut Roux-en-Y reconstruction may have little or no effect on major postoperative complications and incidence of anastomotic ...

Conclusion The modified "Roux en Y" hepatojejunostomy is a simple and new technique to permit an alternative transgastric endoscopic access to biliary-enteric anastomosis.

Methods Retrospective cohort study (database and clinical note review) of use of polyethylene glycol (PEG)-J, transgastric gastrojejunostomy (GJ) tubes and surgical roux-en-Y jejunostomy (ReYJ) in a ...

BACKGROUND: Surgical options for morbid obesity are diverse, and the Roux-en-Y gastric bypass, initially described by Fobi has gained popularity. Knowledge about the physiology of the bypassed stomach ...

Objective Food intake normally stimulates release of satiety and insulin-stimulating intestinal hormones, such as glucagon-like peptide (GLP)-1. This response is blunted in obese insulin resistant ...

Although choledochoduodenostomy was widely performed for choledocholithiasis in the 1960s and 1970s, Roux-en-Y hepaticojejunostomy is currently the preferred biliary-enteric anastomosis for benign and ...